A recent study in gastrointestinal (GI) cancer research reveals a promising advancement in predicting patient responses to immune checkpoint inhibitor (ICI) therapy. The newly developed DNA damage response-related immune activation (DRIA) signature could serve as a groundbreaking biomarker, providing valuable guidance for ICI therapy decisions.
A groundbreaking study has recognized the cGAS-STING signaling pathway as a formidable ally in the immune system's battle against cancer. This pivotal discovery may pave the way for innovative immunotherapies capable of amplifying the body's inherent defenses to detect and eradicate cancer cells, signifying a substantial advance towards more potent cancer treatments.
The following post is by Annmarie Leadman, Director of Communications at the Aeras Global TB Vaccine Foundation and Babs Verblackt, Associate Communications at TuBerculosis Vaccine Initiative – TBVI. Christine Sizemore of the U.S. National Institutes of Health called on the TB vaccine research field to challenge dogma and to think outside the box as scientists […]
Eleven current and former Fogarty International and Doris Duke clinical research fellows made their way to Capitol Hill Thursday for congressional office visits with key legislators. The Center for Global Health Policy staff escorted the group to meetings with the offices of 15 policymakers. The fellows highlighted their research experience abroad through the Fogarty and […]